HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DS-2969b

GyrB inhibitor

Also Known As:

4-chloro-5-ethyl-N-((3S,4R)-1-(5-(2-hydroxypropan-2-yl)-1,3,4 thiadiazol 2 yl)-3-methoxypiperidin-4-yl)-1H-imidazole-2-carboxamide 2-3 hydrate

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Thiadiazoles: 99
        DS-2969b: 4
    - Imidazoles: 150
      - DS-2969b: 4
  - Piperidines: 17
    - DS-2969b: 4
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiadiazoles: 99
      - DS-2969b: 4

Experts

1.	Masuda, Nobuhisa: 4 articles (12/2018 - 01/2018)
2.	Yamada, Makiko: 3 articles (12/2018 - 01/2018)
3.	Dennie, Justin: 2 articles (12/2018 - 01/2018)
4.	Gajee, Roohi: 2 articles (12/2018 - 01/2018)
5.	Inoue, Satoshi: 2 articles (12/2018 - 01/2018)
6.	Senaldi, Giorgio: 2 articles (12/2018 - 01/2018)
7.	Vandell, Alexander G: 2 articles (12/2018 - 01/2018)
8.	Zamora, Cynthia: 2 articles (12/2018 - 01/2018)
9.	Zhang, George: 2 articles (12/2018 - 01/2018)
10.	Barman, Tarani Kanta: 2 articles (01/2018 - 01/2018)

Related Diseases

1.	Clostridium Infections 12/01/2018 - "DS-2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection. " 01/01/2018 - "DS-2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection (CDI). " 01/01/2018 - "DS-2969b is a novel GyrB inhibitor that is currently under clinical development for the treatment of Clostridium difficile infection (CDI). "
2.	Infections 01/01/2018 - "The pharmacokinetics and pharmacodynamics of DS-2969b and DS11960558 against MRSA were characterized in a neutropenic murine thigh infection model; the percentage of time during the dosing period in which the free drug concentration exceeded the MIC (fTMIC) correlated best with in vivo efficacy, and the static percent fTMIC was 43 to 49%. " 01/01/2018 - "DS-2969b and DS11960558 showed efficacy in a neutropenic murine MRSA lung infection model. " 01/01/2018 - "In a neutropenic MRSA-induced murine muscle infection model, DS-2969b was more efficacious than linezolid by both the subcutaneous and oral routes. " 01/01/2018 - "These results suggest that DS11960558 and DS-2969b have potential for use as intravenous-to-oral step-down therapy for treating MRSA infections with a higher efficacy than linezolid."
3.	Body Weight (Weight, Body) 01/01/2018 - "difficile strains at 4× MIC, and the frequency of resistance development was less than 4.8 × 10-9 In a hamster CDI model, 5-day oral administration of DS-2969b conferred complete protection from recurrence and mortality at 0.3 mg/kg of body weight once a day, in contrast to a 50% survival rate with fidaxomicin at 3 mg/kg once a day and 0% with vancomycin at a 50-mg/kg/dose twice a day. "

Related Drugs and Biologics

1.	Vancomycin
2.	Fidaxomicin
3.	Linezolid (Zyvox)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration